The Vaccine Manufacturing and Innovation Centre, in Oxford, was built in 2018 with the goal of developing vaccines to protect against future pandemics, jab shortages and price wars.
But New Jersey-based Catalent has purchased the 74,000-square metre facility for an undisclosed sum. The Daily Mail
See also:
No comments:
Post a Comment